Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of oral and injectable utidelone in HER2-negative advanced breast cancer
CTR20262766Phase 3Active
- Sponsor
- 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司
- Start
- Jul 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone in breast cancer, sponsored by 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司. Started Jul 2026; status: active.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20262766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262766.